Asset purchase is the other side of the coin from asset sale in today’s pharmaceutical development world. Consequently, most of our case studies feature larger companies seeking to enrich their later-stage pipelines. AMS is a useful tool for quickly gaining additional information on clinical metabolism, IV pharmacokinetics and ADME mass balance where this is not fully understood due to lack of investment in these areas by drugs developed by biotech organizations on a tight budget.
Back-fill data package for oral anti-cancer asset in early clinical development acquired from a US biotech company
GI – accelerate gastric emptying and stimulate gastrointestinal motility
Back-fill regulatory package for asset from small company and exhibiting strong melanin binding. Conduct mass balance and metabolite profile using amicrotracer
Client case study links
Xceleron is acquired by Pharmaron
"...AMS [is] an invaluable tool in our early drug development program, allowing us to quickly assess bioavailability in humans and focus resources on our most promising drug candidates going forward."
Find out how we can help you accelerate your drug-development program.